FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
(the “Special Meeting”). As of January 27, 2017, the record date
for the Special Meeting, there were 44,079,447 shares of common
stock issued and outstanding and entitled to vote on the proposals
presented at the Special Meeting, of which 39,004,047, or 88.5%,
were present in person or represented by proxy, which constituted a
quorum. The holders of shares of our common stock are entitled to
one vote for each share held. Set forth below are the final voting
results for each of the proposals submitted to a vote of the
Companys stockholders at the Special Meeting.
Incorporation
the Company’s Restated Certificate of Incorporation, as amended,
to effect a reverse stock split of the Company’s outstanding
shares of common stock at a ratio within a range from 1:3 to 1:10,
with the final ratio to be determined by the Company’s Board of
Directors, in its sole discretion. The voting on this proposal is
set forth below:
|
Shares Voted:
|
For
|
Against
|
Abstentions
|
|||
|
Amendment to Restated Certificate of Incorporation
|
|
36,216,690
|
|
2,746,251
|
|
41,106
|
proxy holder to adjourn the Special Meeting to another time and
place, if necessary, to solicit additional proxies in the event
that there are not sufficient votes to approve Proposal 1. The
voting on this proposal is set forth below:
|
Shares Voted:
|
For
|
Against
|
Abstentions
|
|||
|
Authorization to Adjourn the Special Meeting
|
|
36,178,838
|
|
2,650,143
|
|
175,066
|
because there were sufficient votes in favor of Proposal 1.
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults. FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Recent Trading Information
FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) closed its last trading session up +0.010 at 0.710 with 12,151 shares trading hands.
